Teva Pharmaceuticals has launched a voluntary recall of valsartan-containing products made using active pharmaceutical ingredient from Mylan Pharmaceuticals, which recently issued a voluntary recall of valsartan-containing products as well. Teva's recall includes all lots of amlodipine and valsartan combination tablets and amlodipine, valsartan, and hydrochlorothiazide (HCTZ) combination tablets due to the presence of N-Nitrosodiethylamine (NDEA). The company has recalled other products containing valsartan in recent months after detecting N-Nitrosodimethylamine (NDMA). With the new recall, the company has recalled all of its unexpired valsartan-containing products from the U.S. market. Additional information about the recall is available here.
FDA alerts patients and health care professionals to Teva's recall of valsartan products due to NDEA
FDA Drug Safety and Availability